| Document |
Document Title |
|
WO/2020/028988A1 |
A method is for use with a treatment regime that includes the exposure of a patient to THC. The method comprises the step of administering Theanine to the patient. The Theanine can be L-Theanine. The treatment regime can involve a plural...
|
|
WO/2020/033859A1 |
Various aspects of this disclosure relate to methods to lower the activation energy of the cannabinoid decarboxylation reaction by performing the decarboxylation reaction in the gas phase.
|
|
WO/2020/024977A1 |
The present invention in particular relates to a class of compounds for treating nervous system diseases, the compounds are the compound as shown by formula (I) or a stereoisomer, a geometric isomer, a tautomer, a solvate, a metabolite, ...
|
|
WO/2020/024099A1 |
The present invention discloses a cyclopentadienyl [c] chromium compound and a preparation method therefor wherein a cationic rare earth compound [Ln(CH)3CN) 9] 3+[(AlCl 4) 3] 3–•CH 3 CN is used as a catalyst, and a 2-naphthol is use...
|
|
WO/2020/027206A1 |
This composition includes a polyphenol compound (B) and a solvent, wherein the polyphenol compound (B) is at least one selected from among a compound represented by formula (1) and a resin having a structure represented by formula (2). (...
|
|
WO/2020/025639A1 |
The present disclosure provides compositions that include tetra-O-methylscutellarein, hexamethoxyquercetagetin, or mixtures or combinations thereof, as well as their use as sweeteners or sweetness enhancers.
|
|
WO/2020/024100A1 |
The present invention discloses a method for preparing a cyclopentadienyl [c] chromium compound wherein a cationic rare earth compound [Ln(CH)3CN) 9] 3+[(A1C1 4) 3] 3–•CH 3 CN is used as a catalyst, and methyl thiophenol is used as a...
|
|
WO/2020/024056A1 |
The present technology generally relates to a composition for topical administration or for oral administrations. The composition comprises at least one cannabinoid and at least one absorbable material. In some instances, the at least on...
|
|
WO/2020/028396A1 |
The present invention relates to an analytical method that includes providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms, and providing a probe selected from the group consisting of coumarin-d...
|
|
WO/2020/019289A1 |
The present invention relates to a novel rhodamine dye and an application thereof against pathogenic bacteria. In particular, the present invention relates to a compound represented by the following formula A. In the formula, X- and R1-R...
|
|
WO/2020/021709A1 |
Provided is a method for decomposing a flavonoid glycoside, wherein a flavonoid glycoside-containing raw material is hydrothermally treated to decompose a flavonoid glycoside into a flavonoid.
|
|
WO/2020/021711A1 |
Provided is a method for decomposing a flavonoid glycoside, wherein a flavonoid glycoside is decomposed into a flavonoid by heat-treating a flavonoid glycoside-containing raw material in the presence of an alcohol in a sealed container a...
|
|
WO/2020/022508A1 |
Provided is a method for decomposing a flavonoid glycoside, wherein a flavonoid glycoside-containing raw material is hydrothermally treated to decompose a flavonoid glycoside into a flavonoid.
|
|
WO/2020/019066A1 |
Described herein is a polypeptide comprising the sequence of SEQ ID NO:3 (CsPT3), a variant thereof having at least 80% sequence identity to SEQ ID NO:3, or a fragment of the polypeptide or the variant thereof. Also described herein is a...
|
|
WO/2020/022509A1 |
Provided is a method for decomposing a flavonoid glycoside, wherein a flavonoid glycoside is decomposed into a flavonoid by heat-treating a flavonoid glycoside- containing raw material in the presence of an alcohol in a sealed container ...
|
|
WO/2020/023368A1 |
Described are novel derivatives of pogostone of formula (I) and methods of using the same.
|
|
WO/2020/016239A1 |
The present invention relates to molecules having the following chemical structure (I). The present invention concerns molecules, in particular active as BRAG2 inhibitors and applications thereof. In particular, the invention concerns BR...
|
|
WO/2020/016875A1 |
The present invention relates to a highly economic process for the purification of a cannabinoid acid, more specifically THCA or CBDA, from either a crude cannabis plant material or a cell culture of said cannabis plant, using ion exchan...
|
|
WO/2020/017864A1 |
The present invention pertains to: a novel diphenol derivative, (±)-tylopilusin D, derived from a marine-derived fungus Aspergillus sp.; and a composition for inhibiting protein tyrosine phosphatase 1B, the composition containing the (Â...
|
|
WO/2020/014776A1 |
An oral dispersible film composition comprising at least one active ingredient and a film forming agent, as well as a method of manufacture of same. The oral dispersible film composition can be free of gum resin, and can be utilized to a...
|
|
WO/2020/018839A1 |
A method of activating heteromeric KCNQ2/3, KCNQ3/5, or KCNQ4/5 voltage-gated potassium channels in a cell membrane is described, as are compositions for use with same, as well as methods of reducing neuronal excitability and of ameliora...
|
|
WO/2020/018946A1 |
Systems and methods for accurate optical pH sensing of biofilms are disclosed. In one embodiment, a method of measuring an extracellular pH level using multiple wavelengths emitted by a fluorescent substance includes: exciting the fluore...
|
|
WO/2020/012003A1 |
The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative str...
|
|
WO/2020/011731A1 |
A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, inclu...
|
|
WO/2020/010454A1 |
The current application relates to formulations of cannabinoids comprising one or more carbohydrate excipients. The cannabinoid formulations mitigate the labile properties of cannabinoids; increase water solubility of the cannabinoids; i...
|
|
WO/2020/000080A1 |
A system for preventing and treating the bends and blockages of blood flow, such as heart attacks and ischemic strokes. The system comprises the application of ultrasound, with cooling of the affected body area, to break up and reduce in...
|
|
WO/2019/245188A1 |
Provided in the present specification are a compound represented by chemical formula 1, and a polymer, a colorant composition, a resin composition, a color filter, and a display device, which comprise the compound.
|
|
WO/2019/237769A1 |
The present invention belongs to the technical field of the preparation of precious metal nano materials and ratiometric fluorescent probes, and in particular relates to a method for preparing a melamine ratiometric fluorescent probe bas...
|
|
WO/2019/238495A1 |
The present invention relates to new photochromic, annelated naphthopyrane systems with special substituents R with which rapid lightening speeds can be attained without losses in darkening depth after excitation, and to their use in pla...
|
|
WO/2019/234728A1 |
The present invention provides THCA- and CBDA-derivatives, and pharmaceutical compositions thereof. These compounds are non-classical cannabinoids that are either agonists or antagonists of the peripheral CB1 and/or CB2 receptors, and ar...
|
|
WO/2019/236772A1 |
Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated h...
|
|
WO/2019/236775A1 |
Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic mark...
|
|
WO/2019/232095A1 |
Disclosed are cationic lipids comprising a vitamin substructure and an ionizable nitrogen- containing group. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of l...
|
|
WO/2019/231497A1 |
The present invention is generally directed to the synthesis and use of fluorophores. It is more specifically directed to the synthesis and use of deuterated fluorophores. In one case, the present invention provides a compound of the str...
|
|
WO/2019/228604A1 |
A photochromic compound including a core skeletal structure represented by the following Formula (I), wherein D is oxygen or sulfur; E is oxygen, sulfur, or NR2 '; a is 0 or 1; R1 is hydrogen, or substituted or unsubstituted alkyl; R2 an...
|
|
WO/2019/224536A1 |
The invention relates to enzymes and methods for producing a monoterpenoid compound. In one aspect, the invention is a method for producing a monoterpenoid compound, comprising the steps of (1) providing a monoterpenoid precursor; (2) pr...
|
|
WO/2019/222146A1 |
In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inve...
|
|
WO/2019/218087A1 |
The invention provides methods of preparing cannabinol (CBN) from a cannabis extract comprising hydrocannabinols or from one or more than one synthetic hydrocannabinols comprising double bond positional and stereo isomers thereof. The ca...
|
|
WO/2019/218764A1 |
A method for preparing esculetin in Microsorum fortunei, mainly comprising: crushing dried stems and leaves of Microsorum fortunei, extracting using an ethanol solution, ethyl acetate, separating by means of silica gel column chromatogra...
|
|
WO/2019/214422A1 |
The present invention relates to the technical field of biochemical extraction, and specifically provides a method for extracting natural vitamin E from a deodorized distillate of a rice bran oil. The method comprises firstly removing mo...
|
|
WO/2019/210401A1 |
A solvent free method of concentrating naturally occurring 2 - carboxylic acid cannabinoids contained in fresh Cannabis: THCA (Tetrahydrocannabinolic acid), CBDA (Cannabidiolic acid), CBNA (Cannabinol acid), CBGa (Cannabigerol acid), CBC...
|
|
WO/2019/212211A1 |
A novel chromane derivative, (3'-hydroxy-4'-ethoxybenzyl)-5,6,7-trimethoxy-2H-1-benzopyra
n (SH-17059 (1)) is disclosed herein. This chromane derivative has been found to inhibit blood vessel cell growth and proliferation, providing a pr...
|
|
WO/2019/210422A1 |
The present disclosure relates to Vitamin E derivatives as multi-scale imaging agents. In particular, the present disclosure relates to isotopically labeled Vitamin E derivatives, and their use as multi-scale imaging agents.
|
|
WO/2019/212997A1 |
The present disclosure relates to compositions and methods for the biosynthetic preparation of urolithin compounds, pharmaceutical compositions and kits containing them, and methods of using them.
|
|
WO/2019/213553A1 |
Disclosed herein are polymeric dyes, their preparation, and their uses. Some embodiments relate to their use for detecting biological activity in samples, such as the presence of bacteria in blood.
|
|
WO/2019/205909A1 |
An eutectic crystal of temozolomide and baicalein and a preparation method therefor. Specifically, the X-ray powder diffraction pattern of the eutectic crystal has characteristic peaks at 2theta values of 7.7 ± 0.2°, 8.6 ± 0.2°, and ...
|
|
WO/2019/210103A2 |
Provided herein are inhibitors of SLC26A3, which is an anion (CV, HCO3, oxalate) exchanger expressed in intestinal epithelial cells. SLC26A3 inhibitors have potential utility for treatment of constipation including chronic idiopathic con...
|
|
WO/2019/208043A1 |
[Problem] To provide a method for simply producing various N-unprotected imine compounds inexpensively and safely. [Solution] This method for producing a N-unprotected imine compound comprises reacting a ketone compound and a nitrogen so...
|
|
WO/2019/203491A1 |
The present specification provides a compound of formula 1 and an organic light emitting device comprising same.
|
|
WO/2019/199068A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light emitting diode comprising same.
|
